

Published on FiercePharma (<http://www.fiercepharma.com>)

Brain scans may help docs target which antipsychotics work

August 31, 2012 | By Eric Palmer

One of the hot trends in cancer medication is genetic tests that can tell doctors if a related treatment will work on certain patients. It means patients don't have to go through a litany of treatments and payers don't have to fork out money for a drug that may not help. Now, two companies are coming up with a variation on that theme for antipsychotic drugs. CNS Response (\$CNSO), AssureRx Health and Brain Resource (\$BRRZY) are each offering brain scan tests that are meant to provide physical and mental patterns that will indicate which treatment will work best for specific patients, *Bloomberg* reports. Global sales of [antipsychotics](#) and [antidepressants](#) reached nearly \$50 billion last year, [IMS Health](#) reports. About 11% of Americans 12 and older are treated just for depression, a condition that can lead to suicide and costs U.S. employers an estimated \$34 billion annually in lost productivity, *Bloomberg* says. But it can be difficult to figure which drugs will help which patients and finding a way to do that is something doctors are anxiously awaiting. [Story](#) | [More](#)

Source URL: <http://www.fiercepharma.com/story/brain-scans-may-help-docs-target-which-antipsychotics-work/2012-08-31>